

# Second WHO Model List of Essential In Vitro Diagnostics

---

© World Health Organization 2019. All rights reserved.

The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The final version will be published as an annex to the report of the second meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics in the WHO Technical Report Series.

# Second WHO Model List of Essential In Vitro Diagnostics

---

© World Health Organization 2019. All rights reserved.

The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The final version will be published as an annex to the report of the second meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics in the WHO Technical Report Series.

# Contents

<b>Preface</b>	3
<b>1. Explanatory notes</b>	4
1.1 Introduction	4
1.2 Objective	4
1.3 Scope of the second EDL	4
1.4 Content and presentation	5
1.5 Recommended use of the EDL	6
1.6 Definitions	7
<b>2. Second Model List of Essential In Vitro Diagnostics (EDL)</b>	9
I. List of Essential In Vitro Diagnostics (EDL): For community settings and health facilities without laboratories	9
II. Health care facilities with clinical laboratories	17

## Preface

The second meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD) was held from 18 to 22 March 2019 in Geneva. The objectives of the meeting were among others: to review the first WHO Model List of Essential In Vitro Diagnostics (EDL), to consider submission of new tests and general input from stakeholders, to review and make recommendations for the Second EDL and to discuss on eligibility criteria for prequalification of IVDs.

WHO secretariat prepared a working draft of the second EDL for open consultation and for review by the SAGE IVD members. The proposed Second list was developed based on changes proposed to the first EDL, submissions for new product categories, a suggested list of general laboratory and anatomical pathology tests and a report on therapeutic drug monitoring tests.

All the procedures were transparent and based on input from internal and external stakeholders, SAGE IVD members and members of the public interested in policy or implementation of the EDL. All the suggested changes, submissions, reviews and responses to the reviews were published on the WHO website for comment, and all public comments received were acknowledged.

The agenda and members of the SAGE IVD as well as all background documents, were posted under: [https://www.who.int/medical\\_devices/diagnostics/selection\\_in-vitro/selection\\_in-vitro-meetings/sage-ivd-2nd-meeting](https://www.who.int/medical_devices/diagnostics/selection_in-vitro/selection_in-vitro-meetings/sage-ivd-2nd-meeting).

The Second WHO Model List of Essential In Vitro Diagnostics (EDL) and its explanatory notes, are presented in this document which will become the annex to the report of the second SAGE IVD meeting. The notes describe the objectives, limitations and guidance for its use.

The full report of the Second meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD) is being finalized, to be published in August -September 2019 as part of the WHO Technical Report Series. The final report will present a full description of the methodologies, reviews, evidence, references and recommendations of the SAGE IVD members and will be found at: [https://www.who.int/medical\\_devices/diagnostics/selection\\_in-vitro/en/](https://www.who.int/medical_devices/diagnostics/selection_in-vitro/en/).

# 1. Explanatory notes

## 1.1 Introduction

WHO presents the second Model List of Essential In Vitro Diagnostics (EDL), which extends the first List, published in May 2018.<sup>1</sup> The List recognizes that in vitro diagnostics (IVDs) are essential for advancing universal health coverage, addressing health emergencies and promoting healthier populations, which are the three strategic priorities of the Thirteenth WHO General Programme of Work, 2019–2023.<sup>2</sup>

## 1.2 Objective

The EDL lists IVDs that are recommended by WHO for use in countries. The EDL is not intended to be prescriptive with respect to the IVDs listed or the levels at which they can or should be used; rather, countries should decide which IVDs to select and where to use them, depending on their epidemiology, human resources and infrastructure.

The EDL is expected to provide guidance and serve as a reference for Member States (programme managers, laboratory managers, procurement officers and reimbursement officers) that are developing and/or updating national EDLs for interventions within universal health coverage and for selecting and using IVDs. It will also be informative for United Nations agencies and nongovernmental organizations that support selection, procurement, supply, donation or provision of IVDs and will inform the private medical technology sector about the diagnostic priorities and the IVDs necessary to address global health issues.

## 1.3 Scope of the second EDL

The EDL consists of 122 test categories presented as follows:

- 46 general IVD tests that can be used for routine patient care as well as for the detection and diagnosis of a wide array of disease conditions;
- 69 IVDs intended for the detection, diagnosis and monitoring of specific diseases. The first EDL listed tests for the following WHO priority disease areas: HIV infection, tuberculosis, malaria and hepatitis B and C as well as syphilis and human papillomavirus infection. The second EDL extends the diseases to include noncommunicable diseases, with an extensive new section covering cancer tests as well as a set of general tests, including a new anatomical pathology section; and
- 7 test categories intended for screening of blood donations.

The EDL does *not* name specific test brands but rather consists of test categories described according to their biological targets. When specific products in categories of tests on the EDL have been prequalified by WHO or are recommended by a WHO disease programme, a link is provided to that information, which is updated regularly.

The EDL comprises test types or categories and is not intended for use as a guideline for use of the types of test. The purpose of each test category is stated briefly, and links to WHO guidelines are provided when available. Many tests are used in the context of broader testing strategies, and the results might have to be confirmed or interpreted in accordance with defined clinical signs and symptoms.

The EDL does not specify the desirable minimal performance characteristics for each test category, nor does it state the minimum quality standards to be considered in selecting specific brands of the test types listed. The quality of tests in each category that are on the market in different regions of the world may vary widely, and this should be taken into account when selecting tests for procurement. Some regulatory agencies define the minimum performance standards required for specific tests in order to avoid false results and the consequent treatment decisions.

<sup>1</sup> First WHO model list of in essential vitro diagnostics. Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1017) (<https://apps.who.int/iris/handle/10665/311567>, accessed May 2019).

<sup>2</sup> Draft thirteenth general programme of work, 2019–2023 (document A71/4). Geneva: World Health Organization; 2018 ([http://apps.who.int/gb/ebwha/pdf\\_files/WHA71/A71\\_4-en.pdf](http://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_4-en.pdf), accessed May 2019).

Test safety and performance guidelines and quality standards should be taken into account in selecting diagnostic tests for procurement, when available, and only tests validated for the intended purpose and with regulatory approval from national authorities should be procured.

#### 1.4 **Content and presentation**

The second EDL is presented by health care facility level in two tiers:

- I. Community and health settings without laboratories, with two sections:
  - a. General IVDs for community and health settings without laboratories
  - b. Disease-specific IVDs for community and health settings without laboratories
- II. Health care facilities with clinical laboratories, with three sections:
  - a. General IVDs for clinical laboratories
  - b. Disease-specific IVDs for clinical laboratories
  - c. Disease-specific IVDs for blood screening laboratories

Community and health settings without laboratories are defined as community and health facilities such as health posts and centres, doctors' offices, outreach clinics, ambulatory care and home-based and self-testing. If laboratory facilities are not available, specimens may be collected, transported to and processed at a higher tier of the health system; specimens must be shipped under appropriate conditions in order to obtain reliable results. The tests in this section of the EDL are also assumed to be available, in combination with the extended list in Section II, at healthcare facilities with laboratories.

The title of tier I was changed from that in the first EDL, where it was "Primary health care". The change was made to differentiate between tests that do not require a laboratory (whether basic or not) and those that must be performed in a laboratory. This change resulted in the deletion of some tests from the original first tier, as their performance was deemed by SAGE IVD to require qualified personnel and a basic laboratory.

Health care facilities with clinical laboratories are defined as district, regional, provincial or specialized hospitals or laboratories and national reference laboratories. It is assumed that trained laboratory technologists, laboratory scientists and pathologists, as well as laboratory infrastructure and equipment, are available as required at the appropriate level. All diagnostic tests available at primary care level are assumed to be available at higher levels, as appropriate.

General IVDs are grouped by test discipline – e.g. clinical chemistry, serology, haematology, microbiology; and specific test types within each discipline are listed in alphabetical order – e.g. bilirubin, complete blood count. Disease-specific IVDs are grouped by disease area in alphabetical order.

For each specific test category on the EDL, the following are described:

Test purpose: Intended use of the test

Assay format: The technique on which the test is generally based, e.g. immunoassay, nucleic acid test

Specimen type: The types of specimens that can be used for the test. Although all validated specimen types are listed for each test category, not all tests on the market are validated for all specimen types. Users are requested to always follow the manufacturer's instructions for specimen preparation and storage.

WHO prequalified or recommended products: For each test for which there are name brand products either prequalified or otherwise recommended by WHO, a link is provided.

Link to WHO guidance: If there is WHO guidance on use of the test category, a link is provided to the appropriate site on the WHO website.

In general, the following terms were used for the different test purposes:

- Screening test:<sup>3</sup> Screening tests are used to determine the status of a disease, disorder or other physiological state in an asymptomatic individual. Depending on the nature of the condition and the targeted patient population, screening tests may be used routinely or may be restricted to 'at risk' patients. These tests are designed to evaluate an individual's current state.
- Diagnostic test:<sup>3</sup> Diagnostic tests are used to determine, verify or confirm a patient's clinical condition as a sole determinant. This type of testing also includes sole confirmatory assays (to verify results of previous testing) and sole exclusion assays (to rule out a particular condition). These tests are designed to evaluate a patient's current state.
- Aid to diagnosis:<sup>3</sup> Tests that are used as aids to diagnosis provide additional information to assist in the determination or verification of a patient's clinical status. The test is not the sole determinant. These tests are designed to evaluate a patient's current state.
- Monitoring test:<sup>3</sup> Monitoring tests are used for measuring levels of analytes for the purpose of adjusting treatments or interventions as required. Monitoring tests include:
  - Assays which are used to ensure that an analyte remains within physiological levels or within an established therapeutic drug range. These types of monitoring tests are designed to evaluate an individual's current state.
  - Assays which are used for serial measurement, whereby multiple determinations are taken over time. These types of monitoring tests are typically used for the detection/assessment of disease progression/regression, disease recurrence, minimum residual disease, response/resistance to therapy, and/or adverse effects due to therapy. These types of monitoring tests are designed to evaluate changes in an individual's state.
- Prognostic tests:<sup>3</sup> These tests are used to measure factors linked to clinical outcome irrespective of treatment. Such tests may be used to estimate the natural progression of a disease (i.e. outcome in the absence of treatment), or to determine the likelihood of a clinical outcome irrespective of therapeutic intervention. These tests are designed to evaluate a patient's future state.
- Surveillance test: Performed on populations of interest to track the progression of disease incidence and/or prevalence.
- Staging test: Performed on patients with a confirmed disease or condition to determine its state at the time of diagnosis and establish a baseline to make relevant treatment decisions.

## 1.5 Recommended use of the EDL


- WHO recognizes that, in order to use the EDL effectively and adapt it to national needs, Member States should consider a variety of factors. These include: local demographics and pattern of diseases; treatment facilities; the training and experience of personnel to collect specimens, to perform diagnostics tests, to transport specimens, to interpret test results and to manage diagnostics laboratories; local testing gaps; supply chain; quality assurance capacity; local availability of treatments; financial resources; available infrastructure and environmental factors.
- The EDL should not be read in isolation but in the context of the scope of testing services that meet the clinical needs and expectations of each country in its own testing networks. An illustration of a tiered testing network in resource-limited countries is shown in Fig. 1. The pyramid reflects the fact that there are generally a large number of level I facilities that serve most patients directly. Going up the levels of the system, there are fewer centralized facilities serving fewer patients directly.

<sup>3</sup> Clinical evidence for IVD medical devices – clinical performance studies for in vitro diagnostic medical devices. Study group 5 final document GHTF/SG5/N8:2012. International Medical Device Regulators Forum; 2012 (<http://www.imdrf.org/docs/ghtf/final/sg5/technical-docs/ghtf-sg5-n8-2012-clinical-performance-studies-ivd-medical-devices-121102.pdf>, accessed May 2019).

National reference laboratories and some provincial laboratories may not provide a broad set of consultative services but are rather referral centres for quality assurance and training or for conducting complex tests (either with specimens taken at facilities lower in the system and transported or by receiving patients referred directly from other facilities).<sup>4</sup>

Fig. 1

The types of testing appropriate at each tier will be country-specific and will depend on factors such as access to electricity, reagent-grade water, phlebotomy and specialized human resources<sup>5</sup>



Information to support the selection and use of IVDs on the EDL is available on the WHO Laboratory and in vitro diagnostics website: <https://www.who.int/in-vitro-diagnostic>.

## 1.6 Definitions

**Essential diagnostics** are those that satisfy the priority health care needs of the population and are selected with due regard to disease prevalence, public health relevance, evidence of utility and accuracy and comparative cost-effectiveness.

**In vitro diagnostics**<sup>6</sup> are a subset of medical devices. They are defined as devices which, whether used alone or in combination, are intended by the manufacturer for the in-vitro examination of specimens derived from the human body solely or principally to provide information for diagnosis or monitoring for compatibility purposes. They include reagents, calibrators, control material and test kits.

A **medical device** is any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, intended by the manufacturer to be used, alone or in combination, for human beings, for one or more of the specific medical purpose(s) of:

- diagnosis, prevention, monitoring, treatment or alleviation of disease;
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury;
- investigation, replacement, modification or support of the anatomy or of a physiological process, supporting or sustaining life;
- control of conception;

<sup>4</sup> Consultation on technical and operational recommendations for clinical laboratory testing harmonization and standardization. Geneva: World Health Organization; 2008 ([http://www.who.int/healthsystems/round9\\_9.pdf](http://www.who.int/healthsystems/round9_9.pdf), accessed May 2019).

<sup>5</sup> Guidance for procurement of in vitro diagnostics and related laboratory items and equipment. Geneva: World Health Organization; 2017 ([http://www.who.int/diagnostics\\_laboratory/publications/procurement](http://www.who.int/diagnostics_laboratory/publications/procurement), accessed May 2019).

<sup>6</sup> Definition of the Terms 'Medical Device' and 'In Vitro Diagnostic (IVD) Medical Device' Study Group 1 Final Document GHTF/SG1/N071:2012 (<http://www.imdrf.org/docs/ghrf/final/sg1/technical-docs/ghrf-sg1-n071-2012-definition-of-terms-120516.pdf>, accessed May 2019).



- disinfection of medical devices; or
- providing information by means of in vitro examination of specimens derived from the human body;

and does not achieve its primary intended action by pharmacological, immunological or metabolic means, in or on the human body, but which may be assisted in its intended function by such means.<sup>7</sup>

---

<sup>7</sup> Medical device – full definition. Geneva: World Health Organization; 2019 ([https://www.who.int/medical\\_devices/full\\_definition](https://www.who.int/medical_devices/full_definition), accessed May 2019).

## 2. Second Model List of Essential In Vitro Diagnostics (EDL)

The EDL is presented by health care facility level in two tiers:

- I. Community and health settings without laboratories, with two sections:
  - a. General IVDs for community and health settings without laboratories
  - b. Disease-specific IVDs for community and health settings without laboratories
- II. Health care facilities with clinical laboratories, with three sections:
  - a. General IVDs for clinical laboratories
  - b. Disease-specific IVDs for clinical laboratories
  - c. Disease-specific IVDs for blood screening laboratories

**Note:** The specimen types listed for each diagnostic test category comprise all possible specimens for that category; however, not all test brands within each category will be validated for all the specimen types listed.

Immunoassays are available in various formats – manual microplate assays and automated platforms – with various types of chemical detection (e.g. turbidimetry, chemiluminescence and electrochemiluminescence assays).

### I. List of Essential In Vitro Diagnostics (EDL): For community settings and health facilities without laboratories

These lists contain tests for community settings and health facilities that include health posts and centres, doctors' offices, outreach clinics, ambulatory care and home-based and self-testing. If laboratory facilities are available in community settings, please refer to the IVDs described in Section II. If laboratory facilities are not available, specimens may be collected, transported to and processed at a higher tier of the health system. The tests in this section of the EDL are also assumed to be available, in combination with the extended list in Section II, at healthcare facilities with laboratories.

<b>I.a General IVDs for use in community settings and health facilities without laboratories</b>				
<b>Discipline</b>	<b>Diagnostic test</b>	<b>Test purpose</b>	<b>Assay format</b>	<b>Specimen type</b>
Blood typing	A, B and O and rhesus factor (Rh)	To determine A, B and O groups and Rh type	Slide agglutination test	Capillary whole blood Venous whole blood <sup>1</sup>
Clinical chemistry	Albumin	To detect or monitor kidney disease	Dipstick	Urine
	Bilirubin	To detect or monitor liver disease and bile duct disorders	Dipstick	Urine
	Glucose	<ul style="list-style-type: none"> <li>To diagnose and screen for diabetes and intermediate hyperglycaemia</li> <li>To diagnose hypoglycaemia</li> </ul>	Dipstick	Capillary whole blood Urine
			Glucometer	Capillary whole blood
	Ketones	To diagnose diabetic ketoacidosis	Dipstick	Urine
	Haemoglobin A1c (HbA1c)	To diagnose and monitor diabetes mellitus	Handheld and small analyser	Capillary whole blood
Whole blood lactate	To assess metabolic acidosis, diabetic keto-acidosis, sepsis and dehydration	Handheld analyser	Venous whole blood <sup>1</sup>	
Haematology	Haemoglobin (Hb)	<ul style="list-style-type: none"> <li>To diagnose and monitor anaemia</li> <li>To monitor the safety of certain drugs (e.g. zidovudine for HIV infection)</li> <li>To screen potential blood donors</li> </ul>	Haemoglobinometer	Capillary whole blood Venous whole blood <sup>1</sup>
		<ul style="list-style-type: none"> <li>Clinical marker for certain severe infections (e.g. malaria, viral haemorrhagic fevers)</li> <li>To aid in the diagnosis of intravascular haemolysis, renal conditions, rhabdomyolysis (myoglobinuria)</li> </ul>	Dipstick	Urine
Microbiology	Urinalysis test strips	To detect urinary tract infections	Multi-parameter strips (dipstick)	Urine
Pregnancy testing	Human chorionic gonadotropin (hCG)	To aid in the early detection of pregnancy	Rapid diagnostic test (RDT) (dipstick and cassette), latex agglutination	Urine (early morning)

<sup>1</sup> If a phlebotomist is available.

### I.b Disease-specific IVDs for use in community settings and health facilities without laboratories

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Cholera	<i>Vibrio cholerae</i> antigen	For initial detection or exclusion of a cholera outbreak (Not for use in case management)	RDT	Stool Rectal swab	N/A	Interim technical note: The use of cholera rapid diagnostic tests, (2016) <a href="https://www.who.int/cholera/task_force/Interim-guidance-cholera-RDT.pdf">https://www.who.int/cholera/task_force/Interim-guidance-cholera-RDT.pdf</a>
Hepatitis B virus (HBV) infection	Hepatitis B surface antigen (HBsAg)	To screen for acute and chronic HBV infection: infants > 12 months of age, children, adolescents and adults	RDT	Capillary whole blood Venous whole blood <sup>1</sup>	Public reports of WHO-prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hbsag/public_report/en/">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hbsag/public_report/en/</a>	Guidelines on hepatitis B and C testing (February 2017) <a href="https://apps.who.int/iris/handle/10665/254621">https://apps.who.int/iris/handle/10665/254621</a>
	Hepatitis B e antigen (HBeAg)	Staging to assess need for HBV treatment in chronic HBV infection	RDT	Capillary whole blood Venous whole blood <sup>1</sup>	N/A	
Hepatitis C virus (HCV) infection	Anti-HCV antibody	To screen for HCV infection: infants > 18 months of age, children, adolescents and adults	RDT	Oral fluid Capillary whole blood Venous whole blood <sup>1</sup>	Public reports of WHO prequalified IVDs <a href="http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report">http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report</a>	Guidelines on hepatitis B and C testing (February 2017) <a href="https://apps.who.int/iris/handle/10665/254621">https://apps.who.int/iris/handle/10665/254621</a>

<sup>1</sup> If a phlebotomist is available.

**I.b Disease-specific IVDs for use in community settings and health facilities without laboratories** *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
HIV infection	HIV 1/2 antibody (anti-HIV Ab)	HIV self-testing	RDT	Oral fluid Capillary whole blood Venous whole blood <sup>1</sup>	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/self-testing_public-report/en/">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/self-testing_public-report/en/</a>	Guidelines on HIV self-testing and partner notification (2016) <a href="https://apps.who.int/iris/handle/10665/251655">https://apps.who.int/iris/handle/10665/251655</a>  Consolidated guidelines on HIV testing services (July 2015) <a href="https://apps.who.int/iris/handle/10665/179870">https://apps.who.int/iris/handle/10665/179870</a>
		To diagnose HIV infection: adults, adolescents, children and infants > 18 months of age	RDT	Oral fluid Capillary whole blood Venous whole blood <sup>1</sup>		
	Combined HIV antibody/p24 antigen (anti-HIV/p24 Ag)	For the diagnosis of HIV infection: adults, adolescents, children and infants > 18 months of age	RDT	Capillary whole blood Venous whole blood <sup>1</sup>		
	Qualitative HIV virological nucleic acid test	For diagnosis of HIV infection in infants < 18 months of age	Point-of-care nucleic acid test	Capillary whole blood Venous whole blood <sup>1</sup> Dried blood spots	Public reports of WHO prequalified IVDs <a href="http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/public_report">http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/public_report</a>	

<sup>1</sup> If a phlebotomist is available.

**I.b Disease-specific IVDs for use in community settings and health facilities without laboratories** *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
HIV infection <i>continued</i>	CD4 cell enumeration	<ul style="list-style-type: none"> <li>For staging advanced HIV disease</li> <li>For monitoring response to antiretroviral therapy. (In settings where viral load is not available)</li> </ul>	Point-of-care flow cytometry platform	Capillary whole blood Venous whole blood <sup>1</sup>	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/cd4/public_report">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/cd4/public_report</a>	<p>Consolidated guidelines on HIV testing services (2015) <a href="https://apps.who.int/iris/handle/10665/179870">https://apps.who.int/iris/handle/10665/179870</a></p> <p>Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy (2017) <a href="https://apps.who.int/iris/handle/10665/255884">https://apps.who.int/iris/handle/10665/255884</a></p>
	Cryptococcal antigen	For screening and diagnosis of cryptococcal meningitis in people with advanced HIV disease	RDT	Capillary whole blood Venous whole blood <sup>1</sup>	N/A	<p>Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children (2018) <a href="http://apps.who.int/iris/handle/10665/260399">http://apps.who.int/iris/handle/10665/260399</a></p> <p>Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy (2017) <a href="https://apps.who.int/iris/handle/10665/255884">https://apps.who.int/iris/handle/10665/255884</a></p>

<sup>1</sup> If a phlebotomist is available.

**I.b Disease-specific IVDs for use in community settings and health facilities without laboratories** *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Influenza	Influenza A and B antigen detection	To aid in the diagnosis of seasonal influenza infection  (Not recommended for surveillance testing)	RDT  Instrument-based point-of-care immunoassay	Nasal swab Nasopharyngeal swab Nasopharyngeal aspirate or wash	N/A	Use of influenza rapid diagnostic tests (2010) <a href="https://apps.who.int/iris/handle/10665/44304/">https://apps.who.int/iris/handle/10665/44304/</a>  WHO recommendations on the use of rapid testing for influenza diagnosis: <a href="https://www.who.int/influenza/resources/documents/RapidTestInfluenza_WebVersion.pdf">https://www.who.int/influenza/resources/documents/RapidTestInfluenza_WebVersion.pdf</a>
	Influenza A and B nucleic acid test	For diagnosis of seasonal influenza infection	Point-of-care nucleic acid test	Nasal swab Nasopharyngeal swab Nasopharyngeal aspirate or wash	N/A	Manual for the laboratory diagnosis and virological surveillance of influenza (2011) <a href="https://apps.who.int/iris/handle/10665/44518">https://apps.who.int/iris/handle/10665/44518</a>  Global Epidemiological Surveillance Standards for Influenza: <a href="https://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf">https://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf</a>  Guidance on clinical management of influenza infections: <a href="https://www.who.int/influenza/resources/documents/clinical_management_2012">https://www.who.int/influenza/resources/documents/clinical_management_2012</a>

**I.b Disease-specific IVDs for use in community settings and health facilities without laboratories** *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Malaria	<i>Plasmodium</i> spp. antigens; species-specific (e.g. HRP2) and/or pan-species specific (e.g. pan-pLDH)	For diagnosis of one or more human malaria species ( <i>P. falciparum</i> , <i>P. vivax</i> , <i>P. malariae</i> , <i>P. ovale</i> )	RDT	Capillary whole blood Venous whole blood <sup>1</sup>	Public reports of WHO prequalified IVDs <a href="http://www.who.int/diagnostics_laboratory/evaluations/pq-list/malaria/public_report">http://www.who.int/diagnostics_laboratory/evaluations/pq-list/malaria/public_report</a>	WHO guidelines for the treatment of malaria, third edition (2015) <a href="https://apps.who.int/iris/handle/10665/162441">https://apps.who.int/iris/handle/10665/162441</a>  Malaria rapid diagnostic test performance. Results of WHO product testing of malaria RDTs: Round 8 (2016–2018) <a href="https://www.who.int/malaria/publications/atoz/9789241514965">https://www.who.int/malaria/publications/atoz/9789241514965</a>  WHO good practices for selecting and procuring rapid diagnostic tests for malaria (2011) <a href="https://apps.who.int/iris/handle/10665/44530">https://apps.who.int/iris/handle/10665/44530</a>  Information note on recommended selection criteria for procurement of malaria rapid diagnostic tests <a href="https://www.who.int/malaria/publications/atoz/rdt_selection_criteria">https://www.who.int/malaria/publications/atoz/rdt_selection_criteria</a>

<sup>1</sup> If a phlebotomist is available.



**I.b Disease-specific IVDs for use in community settings and health facilities without laboratories** *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products <sup>1</sup>	WHO supporting documents
Syphilis	Antibodies to <i>Treponema pallidum</i>	For diagnosis or as an aid in the diagnosis of <i>T. pallidum</i>	RDT	Capillary whole blood Venous whole blood <sup>2</sup>	N/A	WHO laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus (2013) <a href="http://apps.who.int/iris/bitstream/handle/10665/85343/9789241505840_eng.pdf">http://apps.who.int/iris/bitstream/handle/10665/85343/9789241505840_eng.pdf</a>
	Combined antibodies to <i>T. pallidum</i> and to HIV-1/2	For diagnosis or as an aid in the diagnosis of HIV-1/2 and/or <i>T. pallidum</i>	RDT	Capillary whole blood Venous whole blood <sup>2</sup>	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv_syphilis/en/">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv_syphilis/en/</a>	WHO Information note on the use of dual HIV/syphilis rapid diagnostic tests (RDT) (2017) <a href="http://apps.who.int/iris/handle/10665/252849">http://apps.who.int/iris/handle/10665/252849</a>
Tuberculosis (TB)	Tuberculin skin (Mantoux) test (TST)	For diagnosis of latent TB infection	Intradermal test	N/A		Latent TB infection: updated and consolidated guidelines for programmatic management (2018) <a href="http://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf">http://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf</a>
Visceral leishmaniasis	rK39 antigen test for visceral leishmaniasis	To aid in the diagnosis of clinically suspected visceral leishmaniasis	RDT	Serum <sup>2</sup> Capillary whole blood Venous whole blood <sup>2</sup>	N/A	WHO Technical Report Series 949 <a href="https://apps.who.int/iris/handle/10665/44412">https://apps.who.int/iris/handle/10665/44412</a>

<sup>1</sup> All TB tests are evaluated and guidelines developed by the WHO global TB programme.

<sup>2</sup> If a phlebotomist is available.

## II. Health care facilities with clinical laboratories

These lists contain additional tests for district, regional, provincial or specialized hospitals or laboratories and national reference laboratories. It is assumed that trained laboratory technologists, specialist expertise and laboratory infrastructure and equipment are available at the appropriate level. All diagnostic tests available in community settings and health facilities as described in Section I are assumed to be available at higher levels, as appropriate. The list comprises sections for:

- a. General IVDs for use in clinical laboratories
- b. Disease-specific IVDs for use in clinical laboratories
- c. Disease-specific IVDs for blood screening laboratories

II.a General IVDs for use in clinical laboratories					
Discipline	Diagnostic test	Test purpose	Assay format	Specimen type	WHO supporting documents
Anatomical pathology <sup>1</sup>	Histopathology	Assessment of tissue for infection, neoplasia, inflammatory and degenerative disorders	Macroscopic assessment of tissue and selection of areas for microscopic examination. Microscopy of tissue sections mounted on slides and stained most commonly with haematoxylin and eosin in the first instance, then treated with a variety of special stains, selected case-by-case to identify pathogens and other abnormal features	Surgical resection Biopsy Core biopsy Cell block	WHO priority medical devices for cancer management <a href="https://apps.who.int/iris/handle/10665/255262">https://apps.who.int/iris/handle/10665/255262</a>  Basic histopathology and anatomical pathology services for developing countries with variable services <a href="https://apps.who.int/iris/handle/10665/119675">https://apps.who.int/iris/handle/10665/119675</a>
	Cytology (cytopathology)	Assessment of cells for infection, neoplasia, inflammatory and degenerative disorders	Microscopy of stained cells on slides	Cervical specimen for Papanicolaou (Pap) smear Body fluids: e.g. cerebrospinal fluid, urine, pleural and peritoneal fluids Fine-needle aspirate (FNA) of lymph node, spleen, other tissues, bone marrow aspirate, sputum, bronchial brushings, bronchoalveolar lavage (BAL), skin samples	

<sup>1</sup> Note: The tests described in this section require specialized anatomical pathology laboratories and trained anatomical pathologists.

## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type	WHO supporting documents
Anatomical pathology <sup>1</sup> <i>continued</i>	Immunohistochemistry (IHC)	Assessment of cells for specific markers to identify infection, neoplasia, inflammatory and degenerative disorders	Microscopy of histopathology tissue sections mounted on slides and stained with antibodies to specific markers. Refer to EDL sections on disease-specific tests for individual assays	Surgical resection Biopsy Core biopsy Cell block	
	Post-mortem examination	Determination of cause of death and correlation with pre-mortem clinical features and investigations	Macroscopic assessment and microscopy of tissue sections. Procedures selected case by case	Cadaver	International guidelines for the determination of death – Phase I <a href="https://www.who.int/patientsafety/montreal-forum-report.pdf">https://www.who.int/patientsafety/montreal-forum-report.pdf</a>

<sup>1</sup> Note: The tests described in this section require specialized anatomical pathology laboratories and trained anatomical pathologists.

## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type
Bacteriology, mycology and parasitology	Urinalysis test strips	Detection of urinary tract infections (UTIs)	Multi-parameter strips including nitrite test	Urine
	Microscopy	Microbial morphology, presence or absence of white blood cells, red blood cells versus squamous epithelial cells for presumptive identification; presence of casts and crystals in urine	Microscopic examination of slides as wet preparations or treated with organism-specific chemical stains (e.g. Gram stain, Giemsa stain, modified Ziehl-Nielsen stain, stains for fungi)	Disease-appropriate specimens (e.g. venous whole blood, urine, stool, cerebrospinal fluid) or cultures
	Culture	Initial step in detection and identification of bacterial and fungal species for selection of appropriate antibiotic regimens	Culture on growth media plates or broth in an incubator followed by recovery of isolates and species identification (traditional manual techniques or automated equipment)	Disease-appropriate specimens (e.g. urine, stool, cerebrospinal fluid, etc.)
	Blood culture	For the detection of bacterial and fungal bloodstream infections (sepsis)	Blood culture bottle in an incubator followed by recovery of isolates (traditional manual techniques or automated equipment)	Venous whole blood
	Genus and species identification of bacteria and fungi	For the identification of the genus or species of bacteria or fungi from cultured isolates	A range of biochemical tests that may be performed manually or on automated equipment.	Isolates from bacterial or fungal cultures
	Antimicrobial susceptibility testing (AST)	Final step in selection of appropriate antibiotics after species identification and interpretation by EUCAST <sup>1</sup> and CLSI guidelines <sup>2</sup>  Note: WHO regards the development of antimicrobial resistance (AMR) a high-priority global health issue. See WHO Global Antimicrobial Resistance Surveillance (GLASS) programme: <a href="http://www.who.int/glass/en/">http://www.who.int/glass/en/</a>	Antimicrobial susceptibility testing of isolates May be done manually by disc diffusion, gradient tests, broth microdilution or automated platforms	Microbial isolates

<sup>1</sup> EUCAST, European Committee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters Version 9.0.

<sup>2</sup> CLSI, Clinical and Laboratory Standards Institute: CLSI M 100 Performance Standards for Antimicrobial Susceptibility Testing, 29th Edition.

## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type
Clinical chemistry	Alanine amino-transferase (ALT)	To assess liver function	Optical methods, automated chemistry analyser if available	Serum Plasma
	Albumin	To detect or monitor malnutrition, kidney, liver disease or malabsorption	Optical methods, automated chemistry analyser if available	Serum Plasma
		To detect or monitor kidney disease	Optical methods, automated chemistry analyser if available	Urine
	Alkaline phosphatase (ALP)	To aid in diagnosis of hepatobiliary diseases and bone disorders	Optical methods, automated chemistry analyser if available	Serum Plasma
	Aspartate amino-transferase (AST)	To assess liver function	Optical methods, automated chemistry analyser if available	Serum Plasma
	Basic metabolic panel (BMP)	To measure the levels of glucose, sodium, potassium chloride, carbon dioxide, blood urea nitrogen (BUN), BUN:creatinine ratio, glomerular filtration rate (eGFR) and may include calcium  <i>Note: Result time sensitive for emergency and critical care</i>	Photometric and colorimetric testing, ion-selective potentiometry (8-parameter automated clinical chemistry analyser)	Venous whole blood Serum Plasma
	Bilirubin	To detect or monitor liver disease, bile duct disorders and red cell destruction	Optical methods, automated chemistry analyser if available	Serum Plasma
	Direct and indirect bilirubin	To detect or monitor liver disease, bile duct disorders and haemolytic anaemia and to differentiate between these causes of jaundice	Optical methods, automated chemistry analyser if available	Serum Plasma

## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type
Clinical chemistry <i>continued</i>	Blood pH and gases	To assess lung function, metabolic or kidney disorders and monitor oxygen therapy	Blood gas analysers, including portable analysers for emergency and critical care	Arterial whole blood
		To measure blood pH, O <sub>2</sub> and CO <sub>2</sub> , serum bicarbonate, anion gap		Venous whole blood
		<i>Note: Result time sensitive for emergency and critical care</i>		
	Blood urea nitrogen (BUN)	To assess kidney function	Optical methods, automated chemistry analyser if available	Serum Plasma
		<i>Note: Result time sensitive for emergency and critical care</i>		
	Comprehensive metabolic panel (CMP)	To measure levels of basic metabolic panel parameters plus magnesium, total protein, albumin, globulin, albumin:globulin ratio, bilirubin (direct or total), alkaline phosphatase (ALP), alanine and aspartate aminotransferases (ALT and AST)	As for basic metabolic panel (14 or more parameter automated clinical chemistry analyser)	Venous whole blood Serum Plasma
C-reactive protein (CRP)	To detect inflammation as an indicator of various conditions, e.g. sepsis, upper respiratory infections	RDT	Venous whole blood	
		Latex agglutination assay	Serum Plasma	
		Immunoassay		
	<i>Note: Result time sensitive for emergency and critical care</i>			
Creatinine	<ul style="list-style-type: none"> <li>To estimate glomerular filtration rate (eGFR) and urine albumin:creatinine ratio (ACR) and urine protein:creatinine ratio</li> <li>To monitor kidney function for management of severe infections (i.e. sepsis, Lassa fever) and antimicrobial regimen adjustment</li> </ul>	Optical methods, automated chemistry analyser if available	Serum Urine	
			<i>Note: Result time sensitive for emergency and critical care</i>	
Electrolytes (sodium, potassium, chloride, bicarbonate)	To monitor fluid, electrolyte and acid-base balance	Automated chemistry analyser	Serum Plasma	
	<i>Note: Result time sensitive for emergency and critical care</i>			

## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type
Clinical chemistry <i>continued</i>	Gamma-glutamyl transferase (GGT)	<ul style="list-style-type: none"> <li>To assess hepatobiliary function</li> <li>To distinguish between bone and hepatobiliary causes of raised ALP</li> </ul>	Optical methods, automated chemistry analyser if available	Plasma Serum
	Glucose	To diagnose and screen for diabetes and intermediate hyperglycaemia, to diagnose hypoglycaemia  <i>Note: Result time sensitive for emergency and critical care</i>	Optical methods, automated chemistry analyser if available	Plasma Serum
	Glucose-6-phosphate dehydrogenase activity (G6PD)	For screening newborns for G6PD deficiency	Semi-quantitative fluorescent spot test	Venous whole blood
	Haemoglobin A1c (HbA1c)	To diagnose and monitor diabetes mellitus	Immunoassay	Venous whole blood
	Lipase or amylase	To assess acute pancreatitis and other pancreatic disorders  <i>Note: Lipase result time sensitive for emergency and critical care</i>	Optical methods, automated chemistry analyser if available	Serum Plasma Peritoneal fluid (amylase)
	Lipid profile	To assess risk of cardiovascular disease (CVD) by measuring cholesterol, triglycerides, low-density lipoproteins (LDL) and high-density lipoproteins (HDL)	Optical methods, automated chemistry analyser if available	Plasma Serum
	Phosphate	<ul style="list-style-type: none"> <li>To monitor chronic kidney disease</li> <li>To prevent and manage tumour lysis syndrome</li> </ul>	Optical methods, automated chemistry analyser if available	Serum Plasma
	Procalcitonin	To guide antibiotic therapy or discontinuation in sepsis and lower respiratory tract infection (For use only in tertiary care facilities and above)	RDT  Point-of-care immunoassay instrument  Immunoassay	Serum Plasma  Venous whole blood Capillary whole blood Plasma  Serum Plasma

## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type
Clinical chemistry <i>continued</i>	Thyroid-stimulating hormone (TSH)	To screen for hypothyroidism and hyperthyroidism	Immunoassay	Serum Plasma Capillary whole blood (neonates)
	Troponin T/I	To diagnose myocardial infarction <i>Note: Result time sensitive for emergency and critical care</i>	Immunoassay (handheld or large automated instrument)	Venous whole blood Serum Plasma
	Uric acid	<ul style="list-style-type: none"> <li>To diagnose and monitor gout</li> <li>To prevent and manage tumour lysis syndrome</li> </ul>	Optical methods, automated chemistry analyser if available	Serum Plasma
	Urine chemistry	To detect and quantify substances in the urine associated with metabolic disorders, renal dysfunction or urinary tract infections <i>Note: Result time sensitive for emergency and critical care</i>	Automated chemical analyser	Urine



## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type
Haematology	Blood cross-matching	To determine blood compatibility for blood transfusions  <i>Note: Result time sensitive for emergency and critical care</i>	Slide and/or tube agglutination test	Venous whole blood Capillary blood
	Complete blood count (CBC) Automated	<ul style="list-style-type: none"> <li>To evaluate overall health and to detect a wide range of disorders, including anaemia, infections, leukaemias, red blood cell, white blood cell and platelet abnormalities and primary immune disorders</li> <li>To diagnose and monitor chemotherapy-associated myelotoxicity</li> </ul> <i>Note: Result time sensitive for emergency and critical care</i>	Automated haematology analyser, total and differential counts of white blood cell (WBC), red blood cell (RBC), platelets, haemoglobin (Hb) and haematocrit (Hct)	Capillary whole blood Venous whole blood
	D-Dimer	To diagnose disseminated intravascular coagulation	Immunoassay	Citrate plasma
	Direct antiglobulin test, (DAT) also known as direct Coombs test	<ul style="list-style-type: none"> <li>To aid in the diagnosis of the cause of immune haemolytic anaemias</li> <li>To investigate a blood transfusion reaction</li> <li>To diagnose haemolytic disease of the newborn</li> </ul>	Red blood cell agglutination	Venous whole blood
	Fibrinogen	To diagnose disseminated intravascular coagulation	Hand-held or automated coagulation analyser (fibrinogen activity)  Enzyme immunoassay (EIA) (fibrinogen antigen)	Citrate plasma
	Haematocrit (Hct)	To diagnose and monitor anaemia  <i>Note: Result time sensitive for emergency and critical care</i>	Micro-haematocrit method (if automated haematology analyser not available)  Haematology analyser (preferred)	Capillary whole blood Venous whole blood

## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type
Haematology <i>continued</i>	Haemoglobin (Hb)	<ul style="list-style-type: none"> <li>To diagnose and monitor anaemia and polycythaemia</li> <li>To monitor the safety of certain drugs (e.g. zidovudine for HIV infection)</li> <li>To screen potential blood donors</li> <li>Clinical marker for certain severe infections (e.g. malaria, viral haemorrhagic fevers)</li> <li>Aid in the diagnosis of intravascular haemolysis, renal conditions, rhabdomyolysis (myoglobinuria)</li> </ul>	Haemoglobinometer, if automated haematology analyser not available <hr/> Haematology analyser (preferred)	Capillary whole blood Venous whole blood
	Indirect antiglobulin test (IAT), also known as indirect Coombs test or red blood cell antibody screen	<ul style="list-style-type: none"> <li>To screen for antibodies to red blood cells before a blood transfusion or in pregnancy</li> <li>To aid in the diagnosis of haemolytic anaemia and blood transfusion reaction</li> </ul>	Red blood cell agglutination	Serum
	Iron studies: Iron Ferritin Total iron-binding capacity (TIBC) or transferrin Calculated transferrin saturation	To diagnose iron deficiency and overload	Optical methods (iron and TIBC) Immunoassay <sup>1</sup> (ferritin and transferrin)	Serum Plasma
	Partial thromboplastin time (PTT), also known as activated partial thromboplastin time (APTT)	<ul style="list-style-type: none"> <li>To diagnose a bleeding disorder or a thrombotic disorder</li> <li>To monitor anticoagulant therapy</li> </ul>	Hand-held or automated coagulation analyser	Citrate plasma
	Peripheral blood film examination	For detection of red blood cell, white blood cell and platelet abnormalities, malignancies and parasites and for white blood cell differential count	Romanowsky stained blood films	Capillary whole blood Venous whole blood

## II.a General IVDs for use in clinical laboratories *continued*

Discipline	Diagnostic test	Test purpose	Assay format	Specimen type
Haematology <i>continued</i>	Platelet count	<ul style="list-style-type: none"> <li>• Diagnosis of thrombocytopenia or thrombocytosis</li> <li>• Marker to manage severe infections associated with bleeding and sepsis (e.g. viral haemorrhagic fever, meningococcaemia) and certain haematological disorders</li> </ul> <p><i>Note: Result time sensitive for emergency and critical care</i></p>	Haemocytometer, if automated haematology analyser is not available	Capillary whole blood Venous whole blood
			Haematology analyser (preferred)	
	Prothrombin time and international normalized ratio (PT/INR)	To detect or diagnose a bleeding disorder or thrombotic disorder (prothrombin time (PT)); monitor performance of anticoagulant medications (International normalized ratio (INR))	Hand-held or automated coagulation analyser	Citrate plasma
	White blood cell count	To aid in the diagnosis of infections and leukaemias	Haemocytometer, if automated haematology analyser not available	Capillary whole blood Venous whole blood
			Haematology analyser (preferred)	
Sickle cell testing	To aid in the diagnosis of sickle cell anaemia, sickle cell trait and other sickling disorders	Sodium metabisulfite slide test	Venous whole blood	
		Haemoglobin solubility		
	For the diagnosis of sickle cell anaemia, sickle cell trait and other sickling disorders	Haemoglobin electrophoresis	Venous whole blood	
Serology	Human chorionic gonadotropin (hCG)	<ul style="list-style-type: none"> <li>• To detect and/or confirm pregnancy</li> <li>• To detect germ cell neoplasms</li> </ul>	Optical method	Serum
			Immunoassay	

II.b Disease-specific IVDs for use in clinical laboratories						
Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Cancer	Alpha-fetoprotein (AFP) immunoassay	For screening for hepatocellular carcinoma (HCC) in high-risk individuals with liver cirrhosis or with a family history, in conjunction with ultrasound  For staging and disease monitoring of germ cell tumours	Immunoassay	Serum Plasma	N/A	Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection (2018). <a href="https://apps.who.int/iris/handle/10665/273174">https://apps.who.int/iris/handle/10665/273174</a>  Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. <a href="https://apps.who.int/iris/handle/10665/154590">https://apps.who.int/iris/handle/10665/154590</a>  WHO classification of tumours of the urinary system and male genital organs. WHO classification of tumours, 4th edition, volume 8. <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016</a>  WHO classification of tumours of female reproductive organs. WHO classification of tumours, 4th edition, volume 6. <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014</a>
	Basic panel for immunohistochemical (IHC) testing for diagnosis of lymphoma	To aid in the diagnosis, sub-classification, prognosis and treatment of lymphoma (including HIV-associated conditions)	IHC testing	Formalin-fixed paraffin-embedded tissue (FFPE) <sup>1</sup>	N/A	WHO classification of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours, revised 4th edition, volume 2. <a href="https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017">https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017</a>

<sup>1</sup> Only for use in specialized anatomical pathology laboratories – see Anatomical Pathology section under II. a General IVDs for use in clinical laboratories.

II.b Disease-specific IVDs for use in clinical laboratories <i>continued</i>						
Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Cancer <i>continued</i>	Basic panel of immunohistochemical (IHC) markers for diagnosis of solid tumours	To aid in diagnosis, prognosis and treatment of solid tumours, especially childhood cancer	IHC testing	Formalin-fixed paraffin-embedded tissue (FFPE) <sup>1</sup>	N/A	WHO classification of tumours, 4th edition. <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours</a>  WHO list of priority medical devices for cancer management <a href="https://apps.who.int/iris/bitstream/handle/10665/255262/9789241565462-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/255262/9789241565462-eng.pdf</a>
	BCR-ABL1 and ABL1 transcripts	For diagnosis and therapeutic monitoring of chronic myelocytic leukaemia (CML) and CML variants (neutrophilic CML) and prognosis of acute lymphoblastic leukaemia (ALL)	Nucleic acid test	Whole blood	N/A	WHO classification of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours, revised 4th edition, volume 2. <a href="https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017">https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017</a>  20th Essential Medicines List (2017) <a href="https://apps.who.int/iris/handle/10665/273826">https://apps.who.int/iris/handle/10665/273826</a>
	Essential flow cytometry panel of antibodies for leukaemia	To aid in the diagnosis of acute leukaemias	Flow cytometry	Bone marrow Peripheral blood Body fluid Tissue Lymph node	N/A	WHO classification of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours, revised 4th edition, volume 2. <a href="https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017">https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017</a>  WHO list of priority medical devices for cancer management. <a href="https://apps.who.int/iris/handle/10665/255262">https://apps.who.int/iris/handle/10665/255262</a>

<sup>1</sup> Only for use in specialized anatomical pathology laboratories – see Anatomical Pathology section under II. a General IVDs for use in clinical laboratories.

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Cancer <i>continued</i>	Faecal immunochemical test (FIT)	Screening for colorectal cancer	Latex agglutination immuno-turbidimetry	Stool	N/A	WHO priority medical devices for cancer management <a href="https://apps.who.int/iris/handle/10665/255262">https://apps.who.int/iris/handle/10665/255262</a>  Colorectal cancer screening. IARC Handbooks of Cancer Prevention, volume 17 <a href="http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Colorectal-Cancer-Screening-2019">http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Colorectal-Cancer-Screening-2019</a>
	Human chorionic gonadotrophin (hCG) plus beta-hCG	To aid in the diagnosis of and surveillance for germ cell tumours and gestational trophoblastic disease	Immunoassay	Plasma	N/A	WHO classification of tumours of the urinary system and male genital organs. WHO classification of tumours, 4th Edition, Volume 8 <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016</a>  WHO classification of tumours of female reproductive organs. WHO classification of tumours, 4th edition, volume 6 <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014</a>

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Cancer <i>continued</i>	Lactate dehydrogenase (LDH) activity	To aid in the prognosis and monitoring of haematological malignancies (lymphoma) and germ cell tumours	Optical methods, automated chemistry analyser if available	Serum Plasma	N/A	<p>WHO classification of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours, revised 4th edition, volume 2  <a href="https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017">https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017</a></p> <p>WHO classification of tumours of the urinary system and male genital organs. WHO classification of tumours, 4th edition, volume 8  <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016</a></p> <p>WHO classification of tumours of female reproductive organs. WHO classification of tumours, 4th edition, volume 6  <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014</a></p>

II.b Disease-specific IVDs for use in clinical laboratories <i>continued</i>						
Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Cancer <i>continued</i>	Oestrogen (ER) and progesterone (PgR) receptors	To aid in diagnosis, prognosis and treatment of breast cancer	Immunohistochemical testing	Formalin-fixed paraffin embedded tissue (FFPE) <sup>1</sup>	N/A	<p>WHO classification of tumours of the breast. WHO classification of tumours, 4th edition, volume 4.  <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Breast-2012">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Breast-2012</a></p> <p>WHO list of priority medical devices for cancer management  <a href="https://apps.who.int/iris/handle/10665/255262/">https://apps.who.int/iris/handle/10665/255262/</a></p> <p>WHO 20th Essential medicines List (2017)  <a href="https://apps.who.int/iris/handle/10665/273826/">https://apps.who.int/iris/handle/10665/273826/</a></p> <p>Guidelines for management of breast cancer. WHO Regional Office for the Eastern Mediterranean (2006)  <a href="http://applications.emro.who.int/dsaf/dsa697.pdf">http://applications.emro.who.int/dsaf/dsa697.pdf</a></p>
	Papanicolaou (Pap) smear test	For screening and as an aid in early diagnosis of cervical cancer	Microscopic examination of cervical cells on slides	Cervical smear from liquid cytology specimen	N/A	<p>Guidelines for screening and treatment of precancerous lesion for cervical cancer prevention. WHO guidelines. (2013)  <a href="https://apps.who.int/iris/handle/10665/94830">https://apps.who.int/iris/handle/10665/94830</a></p>
	Prostate specific antigen (PSA)	To aid in diagnosis, prognosis and monitoring of prostate cancer	Immunoassay	Peripheral blood	N/A	<p>WHO classification of tumours of the urinary system and male genital organs. WHO classification of tumours, 4th edition, volume 8  <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016</a></p>

<sup>1</sup> Only for use in specialized anatomical pathology laboratories – see Anatomical Pathology section under II. a General IVDs for use in clinical laboratories.



## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Cancer <i>continued</i>	Tyrosine-protein kinase receptor (erbB-2) or human epidermal growth factor receptor 2 (HER-2) overexpression	To aid in diagnosis, prognosis and treatment of breast cancer	Immunohistochemical testing as confirmatory test	Formalin-fixed paraffin-embedded tissue (FFPE) <sup>1</sup>  (Referred specimens must be fixed correctly before transport)	N/A	WHO classification of tumours of the breast. WHO classification of tumours, 4th edition, volume 4 <a href="http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Breast-2012">http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Breast-2012</a>  WHO list of priority medical devices for cancer management <a href="https://apps.who.int/iris/handle/10665/255262">https://apps.who.int/iris/handle/10665/255262</a>  WHO 20th Essential Medicines List (2017) <a href="https://apps.who.int/iris/handle/10665/273826">https://apps.who.int/iris/handle/10665/273826</a>

<sup>1</sup> Only for use in specialized anatomical pathology laboratories – see Anatomical Pathology section under II. a General IVDs for use in clinical laboratories.

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Hepatitis B	Hepatitis B virus (HBV) surface antigen (HBsAg)	Screening for acute and chronic hepatitis B virus (HBV) infection: infants > 12 months of age, children, adolescents and adults	RDT <hr/> Immunoassay	Venous whole blood Plasma Serum <hr/> Plasma Serum	Public reports of WHO prequalified IVDs <a href="http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hbsag/public_report">http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hbsag/public_report</a>	Guidelines on hepatitis B and C testing (February 2017) <a href="http://apps.who.int/iris/handle/10665/254621">http://apps.who.int/iris/handle/10665/254621</a>
	Quantitative HBV virological nucleic acid test	Staging to assess the need for treatment in chronic HBV infection and monitoring of response to treatment	Nucleic acid test	Serum Plasma	N/A	
	Hepatitis B e antigen (HBeAg)	Staging to assess the need for treatment in chronic HBV infection	Immunoassay	Serum Plasma	N/A	
	IgM-specific antibodies to hepatitis B core antigen (IgM anti-HBc)	For the diagnosis of acute HBV infection – used for outbreak investigation	Immunoassay	Serum Plasma		
	Antibodies to hepatitis B surface antigen (anti-HBs)	To determine effectiveness of HBV vaccination at individual and population levels. Also used as a marker of recovery from HBV infection	Immunoassay	Serum Plasma	N/A	

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Hepatitis C	Antibodies to hepatitis C virus (HCV) (anti-HCV)	Screening for HCV infection: infants > 18 months of age, children, adolescents and adults	RDT	Capillary whole blood Venous whole blood Plasma Serum	Public reports of WHO prequalified IVDs <a href="http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report">http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report</a>	Guidelines on hepatitis B and C testing (February 2017) <a href="http://apps.who.int/iris/handle/10665/254621">http://apps.who.int/iris/handle/10665/254621</a>
			Immunoassay	Serum Plasma		
	Combined antibodies to HCV (anti-HCV) and HCV core antigen (HCVcAg)	Screening for past or present HCV infection: infants > 18 months of age, children, adolescents and adults	Immunoassay	Serum Plasma		
	HCV core antigen (HCVcAg)	For diagnosis of viraemic HCV	Immunoassay	Serum Plasma		
	Qualitative or quantitative HCV virological nucleic acid	For diagnosis of viraemic HCV and monitoring of response to treatment, and as a test of cure	Nucleic acid test	Capillary whole blood Venous whole blood Serum Plasma		

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
HIV infection	Antibodies to HIV-1/2 (anti-HIV Ab)	For the diagnosis of HIV infection: adults, adolescents, children and infants > 18 months of age	RDT	Venous whole blood Plasma Serum	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-rdts/public_report">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-rdts/public_report</a>	Guidelines on HIV self-testing and partner notification (2016) <a href="http://apps.who.int/iris/handle/10665/251655">http://apps.who.int/iris/handle/10665/251655</a>
			Immunoassay	Serum Plasma		
	Combined HIV antibody/p24 antigen (anti-HIV/p24 Ag)	For the diagnosis of HIV infection: adults, adolescents, children and infants > 18 months of age	RDT	Venous whole blood Plasma Serum	Consolidated guidelines on HIV testing services (July 2015) <a href="https://apps.who.int/iris/handle/10665/179870">https://apps.who.int/iris/handle/10665/179870</a>	WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection, module 10 for testing providers (2017) <a href="http://www.who.int/hiv/pub/prep/prep-implementation-tool">http://www.who.int/hiv/pub/prep/prep-implementation-tool</a>
			Immunoassay	Serum Plasma		
Qualitative HIV virological nucleic acid test	For diagnosis of HIV infection in infants < 18 months of age	Nucleic acid test	Capillary whole blood Venous whole blood Dried blood spots Plasma	Public reports of WHO prequalified IVDs <a href="http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/public_report">http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/public_report</a>	Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (2016) <a href="https://apps.who.int/iris/handle/10665/208825">https://apps.who.int/iris/handle/10665/208825</a>	
		Quantitative HIV virological nucleic acid test	<ul style="list-style-type: none"> <li>For monitoring response to antiviral treatment</li> <li>For diagnosis of HIV infection in infants &lt; 18 months of age (only if validated by the manufacturer)</li> </ul>			Nucleic acid test

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
HIV infection <i>continued</i>	CD4 cell enumeration	<ul style="list-style-type: none"> <li>For staging advanced HIV disease</li> <li>For monitoring response to antiretroviral therapy. (In settings where viral load is not available)</li> </ul>	Flow cytometry	Capillary whole blood Venous whole blood	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/cd4/public_report">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/cd4/public_report</a>	<p>Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (2016) <a href="https://apps.who.int/iris/handle/10665/208825">https://apps.who.int/iris/handle/10665/208825</a></p> <p>Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy <a href="https://apps.who.int/iris/handle/10665/208825">https://apps.who.int/iris/handle/10665/208825</a></p>
	Cryptococcal antigen	For screening and diagnosis of cryptococcal meningitis in people living with advanced HIV disease	RDT	Cerebrospinal fluid Capillary whole blood Venous whole blood Serum Plasma	N/A	Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children (2018) <a href="http://apps.who.int/iris/handle/10665/260399">http://apps.who.int/iris/handle/10665/260399</a>
			Immunoassay	Cerebrospinal fluid Serum Plasma		Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy (2017) <a href="https://apps.who.int/iris/handle/10665/255884">https://apps.who.int/iris/handle/10665/255884</a>
	Histoplasma antigen	To aid in the diagnosis of disseminated histoplasmosis	Immunoassay	Urine	N/A	Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy (2017) <a href="https://apps.who.int/iris/handle/10665/255884">https://apps.who.int/iris/handle/10665/255884</a>
Human papilloma-virus (HPV) Infection	HPV nucleic acid test	For cervical cancer screening	Nucleic acid test	Cervical cells collected in test-specific transport fluid	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/public_report_hpv">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/public_report_hpv</a>	WHO human papillomavirus laboratory manual, first edition (2009) <a href="http://apps.who.int/iris/handle/10665/70505">http://apps.who.int/iris/handle/10665/70505</a>

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Malaria	<i>Plasmodium</i> spp. antigens; species-specific (e.g. HRP2) and/or pan-species-specific (e.g. pan-pLDH)	For diagnosis of one or more human malaria species ( <i>P. falciparum</i> , <i>P. vivax</i> , <i>P. malariae</i> , <i>P. ovale</i> )	RDT	Capillary whole blood Venous whole blood	Public reports of WHO prequalified IVDs <a href="http://www.who.int/diagnostics_laboratory/evaluations/pq-list/malaria/public_report">http://www.who.int/diagnostics_laboratory/evaluations/pq-list/malaria/public_report</a>	WHO guidelines for the treatment of malaria, third edition (2015) <a href="http://apps.who.int/iris/10665/162441">http://apps.who.int/iris/10665/162441</a>  Malaria rapid diagnostic test performance: Results of WHO product testing of malaria RDTs: Round 8 (2016–2018) <a href="https://www.who.int/malaria/publications/atoz/9789241514965">https://www.who.int/malaria/publications/atoz/9789241514965</a>  Information note on recommended selection criteria for procurement of malaria rapid diagnostic tests <a href="https://www.who.int/malaria/publications/atoz/rdt_selection_criteria">https://www.who.int/malaria/publications/atoz/rdt_selection_criteria</a>  WHO good practices for selecting and procuring rapid diagnostic tests for malaria (2011) <a href="http://apps.who.int/iris/handle/10665/44530">http://apps.who.int/iris/handle/10665/44530</a>

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Malaria <i>continued</i>	<i>Plasmodium</i> spp.	For diagnosis of one or more human malaria species ( <i>P. falciparum</i> , <i>P. vivax</i> , <i>P. malariae</i> , <i>P. ovale</i> ) and monitoring response to treatment	Light microscopy	Capillary whole blood Venous whole blood	N/A	WHO guidelines for the treatment of malaria, third edition (2015) <a href="http://apps.who.int/iris/10665/162441">http://apps.who.int/iris/10665/162441</a>  Basic malaria microscopy Part I: Learner's guide (2010) <a href="http://apps.who.int/iris/handle/10665/44208">http://apps.who.int/iris/handle/10665/44208</a>  Malaria microscopy standard operating procedures (2015) <a href="http://www.wpro.who.int/mvp/lab_quality/mm_sop/en/">http://www.wpro.who.int/mvp/lab_quality/mm_sop/en/</a>
	Glucose-6-phosphate dehydrogenase (G6PD) activity	To determine G6PD activity (normal, intermediate, deficient) for a decision to administer 8-aminoquinoline group drugs for radical cure of <i>P. vivax</i> malaria	Semi-quantitative fluorescent spot test	Venous whole blood	N/A	WHO guidelines for the treatment of malaria, third edition (2015) <a href="http://apps.who.int/iris/10665/162441">http://apps.who.int/iris/10665/162441</a>

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Neglected tropical diseases	Qualitative dengue virus nucleic acid test	For surveillance (serotype differentiation) and confirmation of outbreaks	Nucleic acid test	Serum Plasma Filter paper stored blood	N/A	Dengue: guidelines for diagnosis, treatment, prevention and control (2009) <a href="https://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf">https://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf</a>
	Dengue virus antibody (immunoglobulin M) (IgM)	To aid in the diagnosis of dengue fever (always in combination with NS1) and for population surveys	RDT	Serum Venous whole blood	N/A	
			Immunoassay	Venous whole blood Filter paper stored blood Dried blood spots (DBS) Saliva		
	Dengue virus antigen (NS1)	To aid in the diagnosis of dengue fever (always in combination with IgM) and for population surveys	RDT	Serum Venous whole blood	N/A	
Immunoassay			Serum Plasma			
Kato-Katz	For surveillance and diagnosis of soil-transmitted helminthiasis and schistosomiasis caused by <i>Schistosoma mansoni</i> , <i>S. intercalatum</i> , <i>S. japonicum</i> , <i>S. mekongi</i>	Microscope slide examination	Fresh stool	N/A	Video of Kato-Katz method <a href="https://www.who.int/neglected-diseases/preventive-chemotherapy/Basic-Lab-methods-in-human-parasitology/en/index2.html">https://www.who.int/neglected-diseases/preventive-chemotherapy/Basic-Lab-methods-in-human-parasitology/en/index2.html</a>	



## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Primary Immuno-deficiencies	HIV 1/2 antibody (anti-HIV Ab)	For differential diagnosis of primary immunodeficiencies	RDT	Oral fluid Capillary whole blood Venous whole blood	N/A	N/A
	Immunoglobulin plasma levels (IgG, IgA, IgM)	To identify patients with low Ig levels and monitor replacement	Radial immuno-diffusion (RID)	Serum	N/A	
			Immunoassay	Serum Plasma		
Lymphocyte subtype enumeration: CD4, CD8, CD20 and CD15/26 cells  (Refer to HIV infection for enumeration of CD4 cells only)	To aid in the diagnosis of primary and secondary immunodeficiencies	Flow cytometry	Venous whole blood	N/A		

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Sexually transmitted infections	Qualitative test for <i>Chlamydia trachomatis</i> (CT) and <i>Neisseria gonorrhoeae</i> (NG) infections	For the diagnosis of chlamydial and/or gonorrhoeal urogenital disease and extragenital infection	Nucleic acid test	Urine, urethral swabs, endocervical swabs, vaginal swabs, rectal swabs, oropharyngeal swabs, Liquid cytology	N/A	WHO sexually transmitted infection laboratory manual <a href="https://apps.who.int/iris/handle/10665/85343">https://apps.who.int/iris/handle/10665/85343</a>  Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations <a href="https://apps.who.int/iris/handle/10665/246200">https://apps.who.int/iris/handle/10665/246200</a>
	Antibodies to <i>Treponema pallidum</i>	For diagnosis or as an aid in the diagnosis of syphilis	RDT	Venous whole blood Plasma Serum	N/A	WHO laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus (2013) <a href="http://apps.who.int/iris/handle/10665/85343">http://apps.who.int/iris/handle/10665/85343</a>
			Immunoassay	Serum Plasma		
	Antibodies to <i>T. pallidum</i> and to HIV-1/2 (anti-HIV Ab)	For diagnosis or as an aid in diagnosis of HIV-1/2 infection and/or syphilis	RDT	Venous whole blood Plasma Serum	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv_syphilis/en/">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv_syphilis/en/</a>	WHO Information note on the use of dual HIV/syphilis rapid diagnostic tests (RDT) (2017) <a href="http://apps.who.int/iris/handle/10665/252849/">http://apps.who.int/iris/handle/10665/252849/</a>  Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations <a href="https://apps.who.int/iris/handle/10665/246200">https://apps.who.int/iris/handle/10665/246200</a>
	Non-treponemal rapid plasma reagin (RPR) test	For screening for syphilis and monitoring treatment effectiveness	Particle/charcoal agglutination assay	Serum Plasma	N/A	WHO sexually transmitted infection laboratory manual <a href="https://apps.who.int/iris/handle/10665/85343">https://apps.who.int/iris/handle/10665/85343</a>
Non-treponemal venereal disease research laboratory (VDRL) test	For screening, diagnosis and confirmation of neurosyphilis	Flocculation test	Serum Plasma Cerebrospinal fluid	N/A		

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Sexually transmitted infections <i>continued</i>	<i>T. pallidum</i> haemagglutination (TPHA) test	For confirmation of syphilis infection and diagnosis of early and late syphilis infection	Red cell agglutination assay	Serum (preferred) Plasma	N/A	Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus <a href="https://www.who.int/reproductivehealth/publications/rtis/9789241505840">https://www.who.int/reproductivehealth/publications/rtis/9789241505840</a>
	<i>T. pallidum</i> particle agglutination (TPPA) test		Particle agglutination assay		N/A	

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products <sup>1</sup>	WHO supporting documents
Tuberculosis (TB)	<i>Mycobacterium tuberculosis</i> bacteria	For diagnosis, treatment and monitoring of active TB	Microscopy	Sputum or other specimen types	Implementing tuberculosis diagnostics: policy framework (2015) <a href="https://apps.who.int/iris/handle/10665/162712">https://apps.who.int/iris/handle/10665/162712</a>	Compendium of WHO guidelines and associated standards: Ensuring optimum delivery of the cascade of care for patients with tuberculosis, second edition (2018) <a href="https://apps.who.int/iris/handle/10665/272644">https://apps.who.int/iris/handle/10665/272644</a>
		For diagnosis and treatment monitoring of active TB including drug-resistant TB	Bacterial culture	Sputum or other specimen types		
	<i>M. tuberculosis</i> DNA	For diagnosis of active TB and simultaneous detection of rifampicin resistance	Nucleic acid test	Sputum Broncho-alveolar lavage (BAL) or extra-pulmonary TB specimen types	WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF (2017) <a href="http://apps.who.int/iris/handle/10665/254792">http://apps.who.int/iris/handle/10665/254792</a>  Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Policy update (2013) <a href="https://apps.who.int/iris/handle/10665/112472">https://apps.who.int/iris/handle/10665/112472</a>	Implementing tuberculosis diagnostics: policy framework (2015) <a href="https://apps.who.int/iris/handle/10665/162712">https://apps.who.int/iris/handle/10665/162712</a>
	<i>M. tuberculosis</i> DNA	For diagnosis of active TB	Loop-mediated isothermal amplification (LAMP)	Sputum	The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance (2016) <a href="http://apps.who.int/iris/10665/249154">http://apps.who.int/iris/10665/249154</a>	

<sup>1</sup> All TB tests are evaluated and guidelines developed by the WHO global TB programme.

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products <sup>1</sup>	WHO supporting documents
Tuberculosis <i>continued</i>	<i>M. tuberculosis</i> DNA mutations associated with resistance	For detection of resistance to first-line anti-TB medicines	Molecular line probe assay (LPA)	Sputum	The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin: policy update (2016) <a href="https://apps.who.int/iris/handle/10665/250586">https://apps.who.int/iris/handle/10665/250586</a>	Compendium of WHO guidelines and associated standards: Ensuring optimum delivery of the cascade of care for patients with tuberculosis, second edition (2018) <a href="https://apps.who.int/iris/handle/10665/272644">https://apps.who.int/iris/handle/10665/272644</a>
	<i>M. tuberculosis</i> DNA mutations associated with resistance	For detection of resistance for second-line anti-TB medicines	Molecular line probe assay (LPA)	Sputum	The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy update (2016) <a href="http://apps.who.int/iris/handle/10665/246131">http://apps.who.int/iris/handle/10665/246131</a>	Implementing tuberculosis diagnostics: policy framework (2015) <a href="https://apps.who.int/iris/handle/10665/162712">https://apps.who.int/iris/handle/10665/162712</a>
	Drug susceptibility testing with <i>M. tuberculosis</i> culture	To detect resistance to first-line and/or second-line anti-TB medicines	Drug susceptibility testing	Bacterial culture of <i>M. tuberculosis</i>	Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis (2018) <a href="http://www.who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility">http://www.who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility</a>	

<sup>1</sup> All TB tests are evaluated and guidelines developed by the WHO global TB programme.

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products <sup>1</sup>	WHO supporting documents
Tuberculosis <i>continued</i>	Lipoarabino- mannan (LAM) antigen	To aid in the diagnosis of TB in seriously ill HIV-positive inpatients	RDT	Urine	The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy update (2015) <a href="http://apps.who.int/iris/handle/10665/193633">http://apps.who.int/iris/ handle/10665/193633</a>	Compendium of WHO guidelines and associated standards: Ensuring optimum delivery of the cascade of care for patients with tuberculosis, second edition (2018) <a href="https://apps.who.int/iris/handle/10665/272644">https://apps.who.int/iris/handle/ 10665/272644</a>  Implementing tuberculosis diagnostics: policy framework (2015) <a href="https://apps.who.int/iris/handle/10665/162712">https://apps.who.int/iris/handle/ 10665/162712</a>
	Immune response by Interferon- gamma release assay (IGRA)	For diagnosis of latent TB infection	Immunoassay or ELISPOT assay	Venous whole blood		Latent TB Infection: updated and consolidated guidelines for programmatic management (2018) <a href="http://apps.who.int/iris/handle/10665/260233">http://apps.who.int/iris/handle/ 10665/260233</a>

<sup>1</sup> All TB tests are evaluated and guidelines developed by the WHO global TB programme.

## II.b Disease-specific IVDs for use in clinical laboratories *continued*

Disease	Diagnostic test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Zika virus infection	Detection of IgM antibodies to Zika virus	To aid in the diagnosis of suspected Zika virus infection <sup>1</sup>	Immunoassay	Serum (Not to be used with cerebrospinal fluid)	N/A	Laboratory testing for Zika virus infection interim guidance <a href="https://www.who.int/csr/resources/publications/zika/laboratory-testing">https://www.who.int/csr/resources/publications/zika/laboratory-testing</a>
	Virological detection of Zika virus	To diagnose acute Zika virus infection <sup>2,3</sup>	Nucleic acid test	Venous whole blood Serum Plasma Urine CSF	WHO listing through Emergency Use Assessment and Listing (EUAL) procedure: <a href="https://www.who.int/diagnostics_laboratory/eual-zika-virus/zika/en/">https://www.who.int/diagnostics_laboratory/eual-zika-virus/zika/en/</a>	

<sup>1</sup> Because of potential cross-reactivity with dengue and other flaviviruses and persistence of Zika IgM antibody that may reflect infection prior to pregnancy, currently available Zika virus IgM test results should not be used alone for clinical decision-making in pregnancy.

<sup>2</sup> Zika virus RNA is typically detectable in serum by NAT assays only within the first week of infection. A negative result does not rule out infection.

<sup>3</sup> To reduce risk of false-positive results in pregnant women, a positive NAT test should be confirmed by re-extraction and repeat NAT testing of the same specimen.

## II.c Disease-specific IVDs for blood screening laboratories

Organism	Screening test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
Hepatitis B virus (HBV)	Hepatitis B surface antigen (HBsAg)	For screening blood donations for HBV	RDT <sup>1,2</sup>	Capillary whole blood Venous whole blood Plasma Serum	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hbsag/public_report">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hbsag/public_report</a>	Screening donated blood for transfusion transmissible infections: recommendations (2009) <a href="http://apps.who.int/iris/handle/10665/44202">http://apps.who.int/iris/handle/10665/44202</a>
			Particle agglutination assay <sup>1,2</sup>	Plasma Serum		
			Immunoassay <sup>1</sup>	Plasma Serum		
Hepatitis C virus (HCV)	Antibodies to HCV (anti-HCV)	For screening blood donations for HCV	RDT <sup>1,2</sup>	Capillary whole blood Venous whole blood Plasma Serum	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report</a>	
			Immunoassay <sup>1</sup>	Serum Plasma		
	Combined antibodies to HCV (anti-HCV) and HCV core antigen (HCV cAg)	For screening blood donations for HCV	Immunoassay <sup>1</sup>	Serum Plasma		

<sup>1</sup> The only assays recommended for blood screening are those that have been validated for this purpose by the manufacturer.

<sup>2</sup> May be performed in laboratories with small throughput, in remote areas or emergency situations.

NOTE: Please refer to the Haematology section for information on General IVDs for blood transfusion.



II.c Disease-specific IVDs for blood screening laboratories <i>continued</i>						
Organism	Screening test	Test purpose	Assay format	Specimen type	WHO prequalified or recommended products	WHO supporting documents
HIV	Antibodies to HIV-1/2 (anti-HIV Ab) test	For screening blood donations for HIV	RDT <sup>1</sup>	Capillary whole blood Venous whole blood Serum Plasma	Public reports of WHO prequalified IVDs <a href="https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-rdts/public_report">https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-rdts/public_report</a>	Screening donated blood for transfusion transmissible infections: recommendations (2009) <a href="http://apps.who.int/iris/handle/10665/44202">http://apps.who.int/iris/handle/10665/44202</a>
			Particle agglutination assay <sup>1</sup>	Serum Plasma		
			Immunoassay <sup>1,2</sup>	Serum Plasma		
	Combined HIV antibody/p24 antigen (anti-HIV/p24 Ag) test	Immunoassay <sup>1,2</sup>	Serum Plasma			
<i>Treponema pallidum</i>	Antibodies to T. pallidum	For screening blood donations for syphilis	Immunoassay <sup>1,2,3</sup>	Serum Plasma	N/A	
Other transfusion-transmitted organisms	To screen for e.g. <i>Trypanosoma cruzi</i> , human T-lymphotropic virus (HTLV I/II), Zika virus, <i>Babesia</i> and West Nile virus in blood donations, depending on local risk of contamination.		Immunoassay <sup>1,2</sup>	Serum Plasma	N/A	

<sup>1</sup> The only assays recommended for blood screening purposes are those that have been validated for this purpose by the manufacturer.

<sup>2</sup> May be performed in laboratories with small throughput, in remote areas or emergency situations.

<sup>3</sup> In populations with a high incidence of syphilis, screening should be performed with a non-treponemal assay: venereal disease research laboratory (VDRL) or rapid plasma reagin (RPR).

NOTE: Please refer to the Haematology section for information on General IVDs for blood transfusion.

World Health Organization  
Essential Medicines and Health Products  
20 Avenue Appia  
CH1211 Geneva 27  
Switzerland

[edlsecretariat@who.int](mailto:edlsecretariat@who.int)

[https://www.who.int/medical\\_devices/diagnostics/selection\\_in-vitro/en/](https://www.who.int/medical_devices/diagnostics/selection_in-vitro/en/)